Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
12.79
+0.33 (2.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
DAWN Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 107.88 | 75.54 | 61.29 | 29.16 | 4.68 | 1.01 |
Research & Development | 198.23 | 130.52 | 85.62 | 43.58 | 9.1 | 13.9 |
Operating Expenses | 306.11 | 206.06 | 146.91 | 72.74 | 13.78 | 14.91 |
Operating Income | -206.46 | -206.06 | -146.91 | -72.74 | -13.78 | -14.91 |
Interest Expense | - | - | - | - | -0.03 | -2.08 |
Interest & Investment Income | 18.67 | 17.19 | 4.75 | 0 | - | - |
Other Non Operating Income (Expenses) | 109.16 | -0.04 | -0.02 | -0.02 | -30.03 | -0 |
Pretax Income | -83.62 | -188.92 | -142.18 | -72.75 | -43.84 | -16.98 |
Earnings From Continuing Operations | -84.29 | -188.92 | -142.18 | -72.75 | -43.84 | -16.98 |
Minority Interest in Earnings | - | - | - | 2.11 | 3.34 | 4.35 |
Net Income | -84.29 | -188.92 | -142.18 | -70.65 | -40.51 | -12.63 |
Preferred Dividends & Other Adjustments | - | - | - | 99.99 | - | - |
Net Income to Common | -84.29 | -188.92 | -142.18 | -170.64 | -40.51 | -12.63 |
Shares Outstanding (Basic) | 89 | 80 | 65 | 37 | 6 | 6 |
Shares Outstanding (Diluted) | 89 | 80 | 65 | 37 | 6 | 6 |
Shares Change (YoY) | 17.15% | 21.85% | 77.13% | 568.42% | -6.67% | - |
EPS (Basic) | -0.95 | -2.37 | -2.17 | -4.62 | -7.33 | -2.13 |
EPS (Diluted) | -0.95 | -2.37 | -2.17 | -4.62 | -7.33 | -2.13 |
Free Cash Flow | -90.24 | -147.08 | -109.9 | -48.54 | -13.58 | -4.52 |
Free Cash Flow Per Share | -1.01 | -1.84 | -1.68 | -1.31 | -2.46 | -0.76 |
EBITDA | -205.5 | -206.03 | -146.85 | -72.72 | -13.77 | - |
D&A For EBITDA | 0.95 | 0.04 | 0.06 | 0.02 | 0.02 | - |
EBIT | -206.46 | -206.06 | -146.91 | -72.74 | -13.78 | -14.91 |
Source: S&P Capital IQ. Standard template.
Financial Sources.